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PreviewsGATA1 (Gamsjaeger et al., 2011) and
individual BD1 and BD2 of BRD4 asso-
ciation with the K310-acetylated RelA
subunit of inflammatory transcription fac-
tor NF-kB (Zou et al., 2014).
The availability of BD1-selective chemi-
cal inhibitor (BrD1i) Olinone, distinct from
the previously characterized broad BET
inhibitors (BETi) MS417, JQ1, and I-BET
that target both BD1 and BD2 and a
BD2-selective inhibitor (BrD2i) MS765/
RVX-208 (Figure 1B), allows the use of
these pharmacological agents to address
the target selectivity and functional sig-
nificance of BD1 and BD2. Using mouse
oligodendrocyte progenitor cells (OPCs)
that can differentiate into myelin-produc-
ing oligodendrocytes, Gacias et al. (2014)
found that treating OPCs with Olinone
promotes oligodendrocyte differentiation,
as reflected by enhanced myelin-specific
Mag,Mog, andMbp gene expression, ac-
companied by reduced progenitor Hes1,
Hes5, and Gmnn marker expression; but,
surprisingly, treating oligodendrocytes
with broad BET inhibitors such as MS417
that target both BD1 and BD2 actually
hinders differentiation (Figure 1C). This
observation was further confirmed via the
use of additional bromodomain-selective
BET inhibitors, including MS611 BrD1i
and RVX-208/MS765 BrD2i (Figure 1B).
Enhanced myelin formation by BrD1i,
but not BrD2i and BETi, highlights the806 Chemistry & Biology 21, July 17, 2014 ª2need to developmore selective bromodo-
main inhibitors to enrich our molecular
understanding of BD1- and BD2-specific
function in gene targeting and disease
treatment. It would be interesting to deter-
mine whether oligodendrocyte lineage
gene expression is indeed regulated by
BRD2 that is predominantly expressed
in these cells and whether BRD4 and
BRD3 could independently or collabora-
tively regulate progenitor and differenti-
ated oligodendrocyte gene expression
with BRD2. The existence of other evolu-
tionarily conserved regions (e.g., ET,
NPS, and BID) that regulate chromatin
binding and partner association of the
BET family proteins also predicts new
drug development targeting other func-
tionally important regions of the BET
proteins. The recent finding that many
protein kinase inhibitors targeting PLK1
(e.g., BI-2536), JAK2 (e.g., TG-101209
and TG-101348), PI3K (e.g., LY294002
and LY303511), and other kinases also
exhibit strong binding affinity to both
BD1 and BD2 or specifically to BD1
(Ciceri et al., 2014; Dittmann et al., 2014;
Ember et al., 2014; see Figure 1B) raises
not only interest in developing dual
kinase/BET inhibitors for cancer thera-
peutics but also concerns of off-target
effects that require further mechanistic
studies of drug action in various biological
systems.014 Elsevier Ltd All rights reservedREFERENCES
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In this issue of Chemistry & Biology, Kim and colleagues describe their work on optogenetic control of fibro-
blast growth factor receptor (FGFR) signaling. By engineering a chimeric receptor, the authors demonstrate
that FGFR intracellular signaling can be controlled in space and time by blue light.Intracellular signal transduction transmits
external signals into the cell interior to
ensure proper cellular decision making.
Fibroblast growth factor receptor (FGFR)
signaling belongs to a classical family
of signal transduction pathways thatregulates a wide spectrum of biological
events such as development, wound
healing, and angiogenesis. Dysregulation
of FGFR signaling has been associ-
ated with developmental disorders and
cancers.Puzzlingly, many of the key cellular
signaling modules initiated by mem-
brane-bound receptor tyrosine kinases,
like FGFR, activate overlapping sets
of downstream pathways, but with dis-
tinct outcomes. Consequently, a central
Figure 1. Comparison between FGFR Signaling Activated by FGF and Light Stimulation
FGFmay activate multiple isoforms of FGFR through receptor dimerization, while light-controlled optoFGFR1 signaling only activates FGFR1 through CRY2PHR
oligomerization. Light-controlled signaling activation enables superior spatial and temporal dissection of FGFR1 signaling networks.
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Previewsquestion in growth-factor-mediated sig-
nal transduction is how a similar set of
downstream signaling cascades can elicit
diverse yet specific cellular outcomes. In
this issue of Chemistry & Biology, Kim
et al. (2014) introduce a new tool for
addressing this question, showing that
light-controlled activation of signal trans-
duction enables superior spatial and tem-
poral regulation, thus enabling dissection
of the roles of specific receptor types.
FGFR signaling initiates with ligand
binding. Similar to the activation of other
membrane receptor tyrosine kinases,
ligand binding to the extracellular domain
leads to the activation of dimeric FGFRs
and their intracellular kinase domains,
and then they trans-phosphorylate each
other. This event leads to the activation
of multiple downstream signaling cas-
cades, including the mitogen-activated
protein kinase (MAPK/ERK), phosphoino-
sitide 3-kinase (PI3K), and phospholipase
C (PLC). Intriguingly, these downstream
pathways can also be activated by many
other growth factors, including epidermal
growth factors and nerve growth factors,
which lead to completely distinct cellular
functions such as proliferation, growth,
differentiation, migration, survival, and
apoptosis.
Previous research has suggested that
differences in spatiotemporal regulation of
intracellular signaling pathways can confer
specificity to cellular responses (Marshall,
1995). Conventional approaches based
on gain- or loss-of-function geneticmanip-
ulations or small-molecule inhibitors, how-
ever, lack the necessary resolution tomodulate specific changes in space and
time to test this hypothesis. A better
understanding of signaling mechanisms
therefore calls for new tools that can
precisely control intracellular signaling in
both space and time. Recently, several
optogenetic tools have emerged, and they
could potentially transform conventional
ways of studying intracellular signaling
(Kennedy et al., 2010; Levskaya et al.,
2009; Wu et al., 2009; Yazawa et al., 2009).
Optogenetics relies on light-induced
protein interactions to control the activa-
tion state of engineered signaling com-
ponents in cells. Kim and colleagues use
blue light-induced cryptochrome oligo-
merization to trigger the activation of an
engineered FGFR (optoFGFR1) and sub-
sequent signaling pathways (Kim et al.,
2014). Light-controlled activation of this
pathway opens the door for experiments
that rely on spatial and temporal regula-
tion aimed at dissecting the roles of spe-
cific receptor types (Figure 1).
To make an FGFR that can be activated
by blue light (optoFGFR1), the authors en-
gineered a chimeric receptor by inserting
the cytoplasmic regions of FGFR1 be-
tween the N-terminal photolyase homol-
ogy domain of cryptochrome (CRY2PHR)
and a membrane-targeting myristoylation
peptide. CRY2PHR has been shown to
undergo blue light-mediated oligomeriza-
tion (Bugaj et al., 2013; Wend et al., 2013).
Therefore, when optoFGFR1 is exposed
to blue light, CRY2PHR oligomerizes and
brings the catalytic domains of FGFR
into proximity, mimicking ligand-induced
FGFR dimerization and subsequent acti-Chemistry & Biology 21, July 17, 2014vation. Using live cell imaging, a FRET
based sensor, and other standard ap-
proaches for analyzing signaling path-
ways, the authors demonstrated that
blue light can indeed induce phosphoryla-
tion of optoFGFR1 and activate down-
stream ERK, AKT, and PLCg signaling
cascades.
By controlling the temporal patterns of
excitation light, the authors characterized
ERK signaling in response to modulated
light frequency and duration. They found
that high-frequency light stimulation
(10 min interval) leads to sustained ERK
activation, whereas low-frequency light
stimulation (30 min and 60 min) gives
pulsatile patterns of ERK activation. This
result is consistent with a previous study
showing that the Ras/ERK signaling mod-
ule functions as a low-pass filter in trans-
mitting extracellular growth factor signals
(Toettcher et al., 2013).
For spatial control, the authors first
localized the illumination area to a small
circle (5 mm radius) at the cell periphery
and demonstrated that subcellular activa-
tion of FGFR signaling is sufficient to
establish cell polarity and direct cell
migration. Then, the authors established
a ‘‘photo-taxis’’ model by expanding the
illumination to a circular field (160 mm
radius). Cells expressing optoFGFR1
were guided into the light-illuminated
area, similar to directed cell migration in
chemotaxis. Finally, the authors showed
that PI3K and PLCg signaling pathways
are actively involved in the regulation
of cell directionality, whereas inhibiting
ERK activity has a negligible effect. Theseª2014 Elsevier Ltd All rights reserved 807
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Previewsresults support previous findings that
PI3K is an upstream regulator of the Rho
GTPases. Taken together, these results
provide an initial validation of optoFGFR1
for controlling FGFR signaling in space
and time.
Looking forward, the current study
opens up exciting opportunities for study-
ing receptor-mediated intracellular sig-
naling pathways. Because receptor acti-
vation is a general mechanism that cells
use to regulate intracellular signal path-
ways, optogenetic chimeras can be
conveniently generalized to control re-
ceptors of other ligands and subsequent
signaling pathways. However, it should
be noted that blue light induces receptor
oligomerization, in contrast to ligand-
bound receptor dimerization. Oligomeri-
zation and dimerization may orient the ki-
nase domain differently and may lead to a
different phosphorylation ratio of multiple
amino acid residues in the kinase domain.
Therefore, the system should be used808 Chemistry & Biology 21, July 17, 2014 ª2with caution for quantifying relative out-
puts of downstream signaling pathways.
Several previous reports have used the
PhyB-PIF or CRY2-CIB1 binding pairs to
demonstrate optogenetic control of indi-
vidual signaling cascades downstream
of growth factor stimulation including the
ERK (Toettcher et al., 2013; Zhang et al.,
2014) and the AKT (Idevall-Hagren et al.,
2012) pathways. This work adds another
node of regulation at the level of mem-
brane receptor. Overall, these light-based
regulation studies promise greater in-
sights into understanding the spatial and
temporal dimensions of intracellular sig-
nal transduction.
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